These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
226 related articles for article (PubMed ID: 31360335)
1. Human Albumin Impairs Amyloid β-peptide Fibrillation Through its C-terminus: From docking Modeling to Protection Against Neurotoxicity in Alzheimer's disease. Picón-Pagès P; Bonet J; García-García J; Garcia-Buendia J; Gutierrez D; Valle J; Gómez-Casuso CES; Sidelkivska V; Alvarez A; Perálvarez-Marín A; Suades A; Fernàndez-Busquets X; Andreu D; Vicente R; Oliva B; Muñoz FJ Comput Struct Biotechnol J; 2019; 17():963-971. PubMed ID: 31360335 [TBL] [Abstract][Full Text] [Related]
2. Effect of CTerm of human albumin on the aggregation propensity of Aβ1-42 peptide: a potential of mean force study. Dutta N; Borah P; Mattaparthi VSK J Biomol Struct Dyn; 2021 Mar; 39(4):1334-1342. PubMed ID: 32070240 [TBL] [Abstract][Full Text] [Related]
3. S14G-humanin inhibits Aβ1-42 fibril formation, disaggregates preformed fibrils, and protects against Aβ-induced cytotoxicity in vitro. Zhang W; Du Y; Bai M; Xi Y; Li Z; Miao J J Pept Sci; 2013 Mar; 19(3):159-65. PubMed ID: 23349038 [TBL] [Abstract][Full Text] [Related]
4. Peptide and protein mimetics inhibiting amyloid beta-peptide aggregation. Takahashi T; Mihara H Acc Chem Res; 2008 Oct; 41(10):1309-18. PubMed ID: 18937396 [TBL] [Abstract][Full Text] [Related]
5. Soluble aggregates of the amyloid-beta peptide are trapped by serum albumin to enhance amyloid-beta activation of endothelial cells. Reyes Barcelo AA; Gonzalez-Velasquez FJ; Moss MA J Biol Eng; 2009 Apr; 3():5. PubMed ID: 19397812 [TBL] [Abstract][Full Text] [Related]
6. In vitro amyloid-β binding and inhibition of amyloid-β self-association by therapeutic albumin. Milojevic J; Costa M; Ortiz AM; Jorquera JI; Melacini G J Alzheimers Dis; 2014; 38(4):753-65. PubMed ID: 24072068 [TBL] [Abstract][Full Text] [Related]
7. Characterization of monomeric and soluble aggregated Aβ in Down's syndrome and Alzheimer's disease brains. Gkanatsiou E; Sahlin C; Portelius E; Johannesson M; Söderberg L; Fälting J; Basun H; Möller C; Odergren T; Zetterberg H; Blennow K; Lannfelt L; Brinkmalm G Neurosci Lett; 2021 May; 754():135894. PubMed ID: 33848613 [TBL] [Abstract][Full Text] [Related]
8. Protection of Si Nanowires against A Zhao X; Mou C; Xu J; Cui W; Shi Y; Wang Y; Luo T; Guo W; Ye J; Chen W Molecules; 2024 Apr; 29(9):. PubMed ID: 38731472 [TBL] [Abstract][Full Text] [Related]
9. The influence of the carboxyl terminus of the Alzheimer Abeta peptide on its conformation, aggregation, and neurotoxic properties. Soreghan B; Pike C; Kayed R; Tian W; Milton S; Cotman C; Glabe CG Neuromolecular Med; 2002; 1(1):81-94. PubMed ID: 12025818 [TBL] [Abstract][Full Text] [Related]
10. Spatial separation of beta-sheet domains of beta-amyloid: disruption of each beta-sheet by N-methyl amino acids. Sciarretta KL; Boire A; Gordon DJ; Meredith SC Biochemistry; 2006 Aug; 45(31):9485-95. PubMed ID: 16878983 [TBL] [Abstract][Full Text] [Related]
11. In silico and in vitro studies to elucidate the role of Cu2+ and galanthamine as the limiting step in the amyloid beta (1-42) fibrillation process. Hernández-Rodríguez M; Correa-Basurto J; Benitez-Cardoza CG; Resendiz-Albor AA; Rosales-Hernández MC Protein Sci; 2013 Oct; 22(10):1320-35. PubMed ID: 23904252 [TBL] [Abstract][Full Text] [Related]
12. Preparation and characterization of a highly soluble Aβ LeVatte MA; Lipfert M; Ladner-Keay C; Wishart DS Protein Expr Purif; 2019 Dec; 164():105480. PubMed ID: 31425755 [TBL] [Abstract][Full Text] [Related]
13. Decoding the synaptic dysfunction of bioactive human AD brain soluble Aβ to inspire novel therapeutic avenues for Alzheimer's disease. Li S; Jin M; Liu L; Dang Y; Ostaszewski BL; Selkoe DJ Acta Neuropathol Commun; 2018 Nov; 6(1):121. PubMed ID: 30409172 [TBL] [Abstract][Full Text] [Related]
14. Biophysical analyses of synthetic amyloid-beta(1-42) aggregates before and after covalent cross-linking. Implications for deducing the structure of endogenous amyloid-beta oligomers. Moore BD; Rangachari V; Tay WM; Milkovic NM; Rosenberry TL Biochemistry; 2009 Dec; 48(49):11796-806. PubMed ID: 19916493 [TBL] [Abstract][Full Text] [Related]
15. How do membranes initiate Alzheimer's Disease? Formation of toxic amyloid fibrils by the amyloid β-protein on ganglioside clusters. Matsuzaki K Acc Chem Res; 2014 Aug; 47(8):2397-404. PubMed ID: 25029558 [TBL] [Abstract][Full Text] [Related]
16. Commentary: Abeta N- Terminal Isoforms: Critical contributors in the course of AD pathophysiology. Tekirian TL J Alzheimers Dis; 2001 Apr; 3(2):241-248. PubMed ID: 12214065 [TBL] [Abstract][Full Text] [Related]
18. Protective effects of EphB2 on Aβ1-42 oligomer-induced neurotoxicity and synaptic NMDA receptor signaling in hippocampal neurons. Geng D; Kang L; Su Y; Jia J; Ma J; Li S; Du J; Cui H Neurochem Int; 2013 Oct; 63(4):283-90. PubMed ID: 23831214 [TBL] [Abstract][Full Text] [Related]
19. Multiple function fluorescein probe performs metal chelation, disaggregation, and modulation of aggregated Aβ and Aβ-Cu complex. Muthuraj B; Layek S; Balaji SN; Trivedi V; Iyer PK ACS Chem Neurosci; 2015 Nov; 6(11):1880-91. PubMed ID: 26332658 [TBL] [Abstract][Full Text] [Related]
20. A novel monoclonal antibody against the N-terminus of Aβ1-42 reduces plaques and improves cognition in a mouse model of Alzheimer's disease. Xing HY; Li B; Peng D; Wang CY; Wang GY; Li P; Le YY; Wang JM; Ye G; Chen JH PLoS One; 2017; 12(6):e0180076. PubMed ID: 28662102 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]